

July 27, 2023



Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the market, and provide a corporate update.

Conference Call & Webcast:

Date: Thursday, August 10, 2023

Time: 5:00 PM ET

Audio Webcast Only:

[link](#)

Q&A Participant Registration Link*:

[link](#)

(<https://register.vevent.com/register/BI29f5f8f4655b45cf8b92fd8f79f69f8f>)

*Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a unique PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast also can be accessed through a link on the Investor Relations section of Aptose's website [here](#). A replay of the webcast will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended June 30, 2023 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspentinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxetpinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please

visit www.aptose.com.

For further information, please contact:

Aptose Biosciences Inc.

Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com

LifeSci Advisors, LLC

Dan Ferry, Managing Director
617-430-7576
Daniel@LifeSciAdvisors.com



Source: Aptose Biosciences, Inc.